Korean firms gear up for next phase of obesity injection production

South Korean pharmaceutical manufacturers are rapidly expanding capacity to support manufacturing of long‑acting obesity shots, signalling deeper integration with global Big Pharma supply chains.

Companies like G2G Bio and Peptron have raised capital and secured facilities to scale production capacity tied to monthly or weekly obesity treatments. These investments come amid global demand surges for GLP‑1 and related therapies, and interest in tech transfer agreements with multinational developers.

This trend embodies the next industrial phase: not just developing obesity drugs, but producing and delivering them at scale. As demand outpaces current manufacturing footprints, regional capacity expansions will be a key enabler of market growth — especially in Asia where access barriers remain high. Pharma strategists should monitor how supply chain partnerships and biotech‑to‑Big Pharma collaborations evolve in this context.